Fortress Biotech…
USUSDFortress Biotech Inc (US:FBIO) — Biotechnology: Pharmaceutical Preparations. Aantal beurzen waarop de aandelen van het bedrijf worden verhandeld: 1. Op deze pagina — koers en grafiek, dividenden, grootste aandeelhouders en historiek van het aantal aandelen.
Over het bedrijf
- Website
- fortressbiotech.com
- Beleggersrelaties
- fortressbiotech.com/investors
- Sector
- Health Care · Biotechnology: Pharmaceutical Preparations
- Hoofdkantoor
- BAY HARBOR ISLANDS, United States
- CEO
- Lindsay Allan Rosenwald
- Werknemers
- 34
- Opgericht
- 2006
- Uitstaande aandelen
- 33.35 mln.
- Free float
- 21.44 mln.
- Marktkapitalisatie
- 73.37 mln. USD
- Insiders
- 22.7%
- Institutionele beleggers
- 31.43%
- Branche (SIC)
- Pharmaceutical Preparations
- LEI
- 529900DZUWSYUURECK24
- Uitkeringsratio
- 0.4%
- FCF
- —
- Schuld
- 35.0 mln. USDnetto kaspositie
- Dividendreeks
- —
- Winst, FCF en uitbetaalde dividenden — voor de 12 maanden tot 30.06.2026 (het laatste rapport van het bedrijf).
Beschrijving
Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma. It also develops CUTX-101, a copper histidinate injection, which is in FDA approved stage for the treatment of Menkes disease; IV Tramadol, an intravenous formulation, which is in NDA/BLA filed stage for the treatment of post-operative acute pain; Dotinurad, a urate transporter inhibitor, which is in Phase III for the treatment of gout and chronic kidney diseases; CAEL-101, a light chain fibril-reactive monoclonal antibody, which is in Phase III for the treatment of amyloid light chain amyloidosis; and Triplex, a universal recombinant modified vaccinia ankara viral vector vaccine, which is in Phase II for the treatment of cytomegalovirus, anti-human immunodeficiency virus, non-hodgkin lymphoma, and acute lymphoblastic leukemia. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.
Beurzen en tickers
| Beurs | Ticker | Valuta | Prijs | Type |
|---|---|---|---|---|
| US USA Stocks | FBIO | USD | 2.09 +2.45% | gewone aandelen |
Dividenden
Er zijn geen dividenduitkeringen gevonden (gecontroleerd op 11.10.2026). Het bedrijf keert waarschijnlijk geen dividend uit.
Nieuws deze week
Geen nieuws in de afgelopen week. Laatste nieuws: 08.09.2026.
Grootste aandeelhouders
| Houder | Belang | Aandelen | Rapportdatum |
|---|---|---|---|
| ROSENWALD LINDSAY A (Chi… | ≈13.74% | 4.59 mln. | 2026-03-18 |
| WEISS MICHAEL S (Officer… | ≈6.82% | 2.28 mln. | 2026-03-18 |
| JIN DAVID (Chief Financi… | ≈4.95% | 1.65 mln. | 2026-06-22 |
| Vanguard Capital Managem… | 3.11% | 1.04 mln. | 2026-06-30 |
| Opaleye Management Inc. | 2.67% | 890 000 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.09% | 697 802 | 2026-06-30 |
| Mackenzie Financial Corp… | 1.67% | 555 676 | 2026-06-30 |
| GSA Capital Partners LLP | 1.37% | 458 472 | 2026-06-30 |
| Shikiar Asset Management… | 0.92% | 305 469 | 2026-06-30 |
| Geode Capital Management… | 0.9% | 300 521 | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.84% | 279 891 | 2026-06-30 |
| Blackrock Inc. | 0.67% | 224 782 | 2026-06-30 |
| Two Sigma Investments, L… | 0.64% | 213 786 | 2026-06-30 |
| LOBELL JONAH JAY (Direct… | ≈0.58% | 192 397 | 2025-12-31 |
| Bridgeway Capital Manage… | 0.53% | 177 368 | 2026-06-30 |
| Vanguard Fiduciary Trust… | 0.5% | 166 371 | 2026-06-30 |
| Bridgeway Funds, Inc.-Ul… | 0.46% | 152 368 | 2026-06-30 |
| HARVEY JIMMIE (Director) | ≈0.44% | 146 704 | 2025-12-31 |
| Fidelity Concord Street… | 0.43% | 143 183 | 2026-07-31 |
| KLEIN DOV (Director) | ≈0.39% | 130 105 | 2025-12-31 |
| HOENLEIN MALCOLM (Direct… | ≈0.35% | 115 747 | 2025-12-31 |
| LORENZ KEVIN R. (Directo… | ≈0.3% | 101 009 | 2025-12-31 |
| iShares Trust-iShares Mi… | 0.26% | 86 983 | 2026-07-31 |
| LU LUCY (Director) | ≈0.18% | 61 273 | 2024-12-31 |
| Fidelity Concord Street… | 0.15% | 49 320 | 2026-07-31 |
| Fidelity Concord Street… | 0.11% | 35 874 | 2026-07-31 |
| EA Series Trust-EA Bridg… | 0.07% | 25 000 | 2026-06-30 |
| Fidelity Concord Street… | 0.06% | 18 550 | 2026-07-31 |
| VANGUARD Inst. INDEX Fd.… | 0.05% | 18 051 | 2026-06-30 |
